Technology evaluation: GEM-231, Hybridon.

Abstract

GEM-231 (HYBO-165) is an 18mer hybrid oligonucleotide under development by Hybridon for the potential treatment of cancer. Phase I/II dose-escalation trials of GEM-231 in combination with paclitaxel and docetaxel were ongoing in March 2002. At this time, a phase I/II trial of GEM-231 in combination with irinotecan (CPT-11) was initiated in patients with solid tumors. As of February 2003, Hybridon planned to initiate phase II trials in 2003.

• Authors: Pollen K F Yeung
• Journal: Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 5 Issue 3 Pg. 315-20 (Jun 2003) ISSN: 1464-8431 [Print] England
• PMID: 12870443 (Publication Type: Evaluation Study, Journal Article)

Chemical References

• Antineoplastic Agents
• GEM231
• Oligonucleotides

Topics

• Animals
• Antineoplastic Agents (adverse effects, metabolism, pharmacology, therapeutic use)
• Cell Line
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Humans
• Neoplasms (drug therapy)
• Oligonucleotides (adverse effects, metabolism, pharmacology, therapeutic use)